

US health worker has serious allergic reaction to Pfizer vaccine

16 December 2020



Two health workers in Britain had similar allergic reactions, causing the government there to tell people to avoid getting the shot if they had a history of severe allergies

A health worker in Alaska suffered a serious allergic reaction after getting Pfizer-BioNTech's COVID-19 vaccine and is now hospitalized but stable, a report said Wednesday.

The New York Times reported the person received their shot on Tuesday, and Pfizer confirmed it was working with [local authorities](#) to investigate the incident.

Two health workers in Britain had similar allergic reactions, causing the government there to tell people to avoid getting the shot if they had a history of severe allergies.

The US regulator issued an emergency approval with the warning that people who had known allergies to ingredients inside the vaccine should avoid it.

"We don't yet have all the details of the report from Alaska about a potential serious allergic reactions

but are actively working with local health authorities to assess," a Pfizer spokesperson said.

"We will closely monitor all reports suggestive of serious allergic reactions following vaccination and update labeling language if needed."

Volunteers for Pfizer's clinical trial of 44,000 people were excluded if they had a history of allergic reactions to vaccines or components of the COVID-19 vaccine.

Overall, the trial found no serious safety issues, but regulators and the company are continuing to monitor for adverse events after vaccination.

The US is vaccinating some three million people this week with the vaccine, and hopes to reach a total of 20 million people this month if another [vaccine](#), developed by Moderna, is approved.

© 2020 AFP

APA citation: US health worker has serious allergic reaction to Pfizer vaccine (2020, December 16) retrieved 9 September 2022 from <https://medicalxpress.com/news/2020-12-health-worker-allergic-reaction-pfizer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.